Form 4: OneMedNet CMO Boosts Stake with Conversions, Purchases, RSUs

OneMedNet Corp's Chief Medical Officer, Jeffrey Yu, significantly increased his direct beneficial ownership through debt conversions, a private placement, and open market purchases, alongside RSU grants.

Summary

• Jeffrey Yu, Chief Medical Officer and Director of OneMedNet Corp, reported substantial changes in his beneficial ownership of common stock.
• On June 17, 2025, Yu converted Senior Secured Convertible Notes into 479,270 shares of common stock at a conversion price of $1.14 per share.
• On June 19, 2025, approximately $1.3 million of outstanding shareholder and business combination extension loans were converted into 1,828,279 shares of common stock at $0.71 per share.
• On June 20, 2025, Yu purchased 1,666,666 shares of common stock at $0.42 per share through a subscription agreement, generating $700,000 in gross proceeds for the issuer.
• Between August 19, 2025, and September 25, 2025, Yu made multiple open market purchases, acquiring a total of 293,009 shares at weighted average prices ranging from $0.69 to $1.03.
• On November 24, 2025, Yu was granted 200,000 Restricted Stock Units (RSUs) as employment compensation, vesting over three years starting January 1, 2025.
• On November 26, 2025, Yu was granted an additional 45,000 RSUs as director compensation for fiscal year 2025, vesting on December 31, 2025.
• Following these transactions, Yu directly beneficially owns 7,326,223 shares of common stock.
• Additionally, 1,311,970 shares are held indirectly by a trust for children, though Yu disclaims beneficial ownership of these shares.

Sentiment

Score: 8

Explanation: The sentiment is positive due to substantial insider accumulation of shares through various means (debt conversion, direct purchase, open market buying, RSU grants). This indicates strong confidence from a key executive in the company's future value and a willingness to convert debt to equity, strengthening the balance sheet. The capital raise also provides funds to the company.

Positives

• Significant insider buying and conversions demonstrate strong confidence from a key executive and director in the company's future.
• Conversion of approximately $1.3 million in shareholder loans to equity reduces the company's debt burden and strengthens its balance sheet.
• The subscription agreement generated $700,000 in gross proceeds for the issuer, providing capital for operations.
• The acquisition of RSUs aligns management's interests with long-term shareholder value through equity incentives.

Negatives

• Some shares were acquired at relatively low prices (e.g., $0.42 per share in the subscription agreement), which could indicate a lower valuation perception at the time of those specific transactions.
• The conversion of notes and loans into common stock, along with the private placement, results in dilution for existing shareholders.

Risks

• The PIPE Notes had a conversion price floor of $1.14, indicating potential for conversion at lower market prices if the stock traded below $10.00, leading to more shares issued.
• RSUs are subject to vesting conditions, meaning the shares are not fully owned until specific service requirements are met, which could impact long-term retention if conditions are not met.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedules for granted Restricted Stock Units.

Industry Context

This Form 4 filing primarily details insider ownership changes and does not provide specific industry context. However, significant insider accumulation, especially through debt-to-equity conversions and direct purchases, can signal management's belief in the company's future prospects within its sector.

Related Party Transactions

• Conversion of Senior Secured Convertible Notes by Jeffrey Yu, an officer and director.
• Conversion of approximately $1.3 million of shareholder loans and business combination extension loans by Jeffrey Yu.
• Subscription agreement for the purchase of 1,666,666 shares of common stock by Jeffrey Yu, generating $700,000 in gross proceeds for the issuer.
• Grant of 200,000 Restricted Stock Units (RSUs) to Jeffrey Yu as employment compensation.
• Grant of 45,000 Restricted Stock Units (RSUs) to Jeffrey Yu as director compensation.

Stakeholder Impact

• Shareholders: The conversions and private placement result in dilution, but the significant insider buying may instill confidence in the company's prospects.
• Creditors: Conversion of shareholder loans to equity reduces the company's debt, potentially improving its credit profile.
• Employees (specifically Jeffrey Yu): Increased equity ownership through RSUs and purchases aligns interests with long-term company performance.

Next Steps

• Vesting of 200,000 employment compensation RSUs: one-third on January 1, 2026, with remaining vesting in equal quarterly installments over the subsequent two years.
• Vesting of 45,000 director compensation RSUs on December 31, 2025.

Key Dates

Recommendation

The substantial increase in beneficial ownership by a key executive and director, Jeffrey Yu, through multiple avenues including debt-to-equity conversions, a private placement, and open market purchases, signals strong insider confidence. This aggressive accumulation, coupled with the company receiving capital from the private placement and reducing debt through conversions, suggests a positive outlook from those closest to the company's operations. While dilution occurs, the insider's conviction and balance sheet strengthening are compelling factors for a 'buy' recommendation.

Keywords

OneMedNet Corp, ONMD, Jeffrey Yu, Insider Buying, Form 4, Beneficial Ownership, Common Stock, Restricted Stock Units, Debt Conversion, Private Placement, Shareholder Loans, Corporate Governance